Dasatinib - Tyrosine Kinase Inhibitor for Chronic Myeloid Leukaemia (CML)
Key Data:
Drug (brand / generic)
Srycel (dasatinib)
Company / licensee
Bristol-Myers Squibb
Therapy class
Anti-neoplastic agent
Product description
Tyrosine Kinase Inhibitor (TKI)
Current indication
CML
Market sector
Oncology
Development status
Approved US and Europe
